Gen2 Neuroscience Company

Gen2 Neuroscience is a dementia drug discovery company. They develop therapeutics for the treatment of dementia targeting abnormal forms of the essential cellular protein tau. Their work focuses on preventing the spreading of the disease throughout the brain by controlling the movement of toxic forms of the tau protein between neurons. Using state-of-the-art stem cell technology, they are identifying extracellular, pathogenic forms of tau. The company's goal is to develop therapeutics specifically targeting disease-associated tau to halt disease progression.
Industry: NeuroTech
Headquarters: Manchester, United Kingdom
Founded Date: 2016
Employees Number: 1-10
Funding Status: Seed
Investors Number: 1
Last Funding Date: 06-03-2016
Last Funding Type: Seed

Visit Website
Register and Claim Ownership